TRPV4 and ATP-Gated P2X Receptor Interaction in Cough Hypersensitivity

Study Background and Research Question

Chronic cough, particularly when refractory or of unknown etiology, remains a significant clinical challenge, often categorized as cough hypersensitivity syndrome (CHS). While increased sensitivity of airway sensory nerves is recognized in CHS, the molecular mechanisms underlying this sensitization are incompletely understood. Previous studies have implicated both the transient receptor potential vanilloid subtype 4 (TRPV4), a Ca²⁺-permeable cation channel, and the purinergic ATP-gated P2X receptors in cough regulation. However, the precise interplay between TRPV4 activation and P2X receptor-mediated signaling in cough hypersensitivity had not been directly addressed. The reference study by Li et al. (Biomolecules 2025) aimed to elucidate these interactions and clarify their role in the pathogenesis of cough hypersensitivity.

Key Innovation from the Reference Study

The central innovation of Li et al.'s work lies in identifying a functional crosstalk between TRPV4 activation and ATP-P2X receptor signaling as a driver of cough hypersensitivity. By integrating behavioral, electrophysiological, and molecular assays in a guinea pig model, the study demonstrates that TRPV4 activation promotes ATP release from airway epithelial cells, which in turn potentiates P2X3, P2X4, and P2X7 receptor-mediated sensory nerve activation. This mechanistic insight delineates a novel pathway contributing to peripheral airway hypersensitivity and persistent cough, with implications for targeted therapeutic strategies.

Methods and Experimental Design Insights

The investigators established a guinea pig model of cough hypersensitivity using repeated citric acid exposure to induce enhanced cough responses, mimicking features of chronic cough in humans. Key methodological approaches included:

• Quantitation of cough frequency following pharmacological manipulation (TRPV4 agonists/antagonists, P2X antagonists) to assess functional outcomes.
• Measurement of ATP and neuropeptide (SP and CGRP) concentrations in bronchoalveolar lavage fluid via enzyme-linked immunosorbent assay (ELISA).
• Analysis of TRPV4 and P2X receptor expression in tracheal carina and vagal ganglion tissues through Western blot and immunohistochemistry, employing enzyme-conjugated antibodies for signal detection.
• Electrophysiological evaluation of vagal ganglion neurons using the whole-cell patch clamp technique to measure ATP-induced inward currents (I_ATP), and assessment of the effects of TRPV4 and P2X modulation.
• Calcium imaging to monitor intracellular Ca²⁺ dynamics in response to receptor activation in isolated vagal neurons.

This comprehensive strategy enabled the authors to connect molecular, cellular, and behavioral endpoints, strengthening the causal link between TRPV4-P2X signaling and cough hypersensitivity.

Core Findings and Why They Matter

The study reports several interrelated findings (Li et al., Biomolecules 2025):

• TRPV4 activation increases cough sensitivity: Administration of a TRPV4 agonist (GSK1016790A) led to a significant increase in cough frequency, while TRPV4 antagonism (HC067047) reduced cough responses in the chronic cough model.
• P2X receptor antagonists suppress cough: Inhibition of P2X3, P2X4, and P2X7 receptors with selective antagonists markedly decreased cough events, indicating their contributory role.
• Upregulation of TRPV4 and P2X expression: Both TRPV4 and P2X3/4/7 receptor levels were elevated in the tracheal carina and vagal ganglia of chronic cough animals, confirmed by Western blot and immunohistochemistry. This upregulation was attenuated by TRPV4 blockade.
• Enhanced ATP release and neuropeptide secretion: Increased ATP, substance P (SP), and calcitonin gene-related peptide (CGRP) levels were detected in lavage fluid from chronic cough animals, with reductions seen after TRPV4 or P2X antagonism.
• Electrophysiological evidence for TRPV4-P2X synergy: Vagal neuron patch clamp recordings revealed that TRPV4 activation potentiates ATP-induced inward currents, which are sensitive to P2X3/4/7 blockade, and that TRPV4 antagonists partially inhibit these currents. Calcium imaging supported these results, showing greater Ca²⁺ influx in chronic cough neurons.

Together, these results support a model in which TRPV4 activation leads to ATP release, stimulating P2X receptors on airway sensory nerves and amplifying cough sensitivity. The demonstration of this pathway provides a molecular basis for refractory cough and highlights potential intervention points.

Comparison with Existing Internal Articles

Several internal resources provide context and methodological parallels for the reference study's approach. For instance, the article "Affinity-Purified Goat Anti-Mouse IgG (H+L), HRP: Elevate..." emphasizes the critical role of affinity-purified, HRP-conjugated secondary antibodies in enabling sensitive and specific detection in Western blot, ELISA, and IHC assays. This aligns closely with the detection methods used by Li et al., where robust immunodetection was essential for quantifying receptor expression and validating experimental manipulations.

Moreover, the discussion in "HRP Goat Anti-Mouse IgG (H+L) Antibody: Molecular Insight..." offers mechanistic perspectives on signal amplification in immunoassays, echoing the technical requirements for detecting subtle changes in protein expression, such as those reported for TRPV4 and P2X receptors in the chronic cough model. These internal articles reinforce the necessity of high-performance HRP-conjugated secondary antibodies—such as the Affinity-Purified Goat Anti-Mouse IgG (H+L), HRP conjugated—for reproducible and quantitative immunodetection in neurobiological and immunological research.

Limitations and Transferability

While the guinea pig model recapitulates key features of human cough hypersensitivity, there are inherent limitations in translating findings directly to clinical contexts. Species-specific differences in airway neurobiology and immune responses must be considered. Furthermore, pharmacological tools used to modulate TRPV4 and P2X receptors may have off-target effects or different efficacy in human tissues. The study did not address long-term consequences of repeated TRPV4 or P2X modulation or potential compensatory changes in other signaling pathways. As such, while the mechanistic insights are compelling, further validation in human tissues or clinical studies is needed to fully assess therapeutic potential.

Protocol Parameters

• Chronic cough induction: Repeated citric acid aerosol exposure in guinea pigs to model airway hypersensitivity.
• Pharmacological treatments: TRPV4 agonist (GSK1016790A) and antagonist (HC067047); P2X3 (A317491), P2X4 (PSB12062), and P2X7 (A804598) antagonists administered to evaluate functional roles.
• Immunodetection: Western blot and IHC performed on tracheal and vagal ganglia tissues using enzyme-conjugated secondary antibodies for signal amplification.
• Electrophysiology: Whole-cell patch clamp analysis of ATP-induced inward currents in isolated vagal ganglion neurons.
• Calcium imaging: Measurement of intracellular Ca²⁺ changes in response to receptor activation.

Research Support Resources

To facilitate comparable workflows in immunodetection, researchers may utilize the HRP Goat Anti-Mouse IgG (H+L) Antibody (SKU K1221) from APExBIO. This affinity-purified, horseradish peroxidase conjugated secondary antibody is suitable for Western blotting, ELISA, and immunohistochemistry, supporting sensitive and specific detection of mouse primary antibodies. For optimal results, follow recommended storage at 4°C short-term or at -20°C for long-term stability, as described in the product information. Selection of high-quality secondary antibodies is critical for reliable signal amplification in immunoassays, especially when quantifying low-abundance targets such as TRPV4 and P2X receptors in complex tissues.